Stem cells for the treatment of neurodegenerative diseases

Stem Cell Research and Therapy

Volumn 1, Issue 5, 2010, Pages

  Dantuma, Elise ^a   Merchant, Stephanie ^a   Sugaya, Kiminobu ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CHOLINESTERASE INHIBITOR; LEVODOPA; MEMANTINE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN REGION; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; DEGENERATIVE DISEASE; DISEASE ACTIVITY; DRUG MECHANISM; GENETIC TRANSFECTION; HUMAN; MESENCHYMAL STEM CELL TRANSPLANTATION; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; NEURAL STEM CELL TRANSPLANTATION; NONHUMAN; PARKINSON DISEASE; PATIENT SAFETY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; STEM CELL TRANSPLANTATION; THERAPY EFFECT; TREATMENT PLANNING;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CELL- AND TISSUE-BASED THERAPY; HUMANS; MULTIPLE SCLEROSIS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 79951730926     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt37     Document Type: Review

References (74)

1. The possible use of stem cells in regenerative medicine: dream or reality? Ehnert S, Glanemann M, Schmitt A, Vogt S, Shanny N, Nussler NC, Stockle U, Nussler A, Langenbecks Arch Surg 2009 394 985 997 10.1007/s00423-009-0546-0 19644703
2. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Becker AJ, McCulloch EA, Till JE, Nature 1963 197 452 454 10.1038/197452a0 13970094
3. The distribution of colony-forming cells among spleen colonies. Siminovitch L, McCulloch EA, Till JE, J Cell Physiol 1963 62 327 336 10.1002/jcp.1030620313 14086156
4. Stem cells: a revolution in therapeutics-recent advances in stem cell biology and their therapeutic applications in regenerative medicine and cancer therapies. Mimeault M, Hauke R, Batra SK, Clin Pharmacol Ther 2007 82 252 264 10.1038/sj.clpt.6100301 17671448 (Pubitemid 47260547)
5. The ethics of embryonic stem cells - now and forever, cells without end. Juengst E, Fossel M, JAMA 2000 284 3180 3184 10.1001/jama.284.24.3180 11135785 (Pubitemid 32039084)
6. Ethical and social considerations of stem cell research. McLaren A, Nature 2001 414 129 131 10.1038/35102194 11689959 (Pubitemid 33041638)
7. Critical issues of clinical human embryonic stem cell therapy for brain repair. Li JY, Christophersen NS, Hall V, Soulet D, Brundin P, Trends Neurosci 2008 31 146 153 10.1016/j.tins.2007.12.001 18255164
8. Concise review: recent advances on the significance of stem cells in tissue regeneration and cancer therapies. Mimeault M, Batra SK, Stem Cells 2006 24 2319 2345 10.1634/stemcells.2006-0066 16794264 (Pubitemid 44679695)
9. Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression. Eminli S, Utikal J, Arnold K, Jaenisch R, Hochedlinger K, Stem Cells 2008 26 2467 2474 10.1634/stemcells. 2008-0317 18635867
10. Generation of human induced pluripotent stem cells from dermal fibroblasts. Lowry WE, Richter L, Yachechko R, Pyle AD, Tchieu J, Sridharan R, Clark AT, Plath K, Proc Natl Acad Sci USA 2008 105 2883 2888 10.1073/pnas.0711983105 18287077 (Pubitemid 351723638)
11. Generation of germline-competent induced pluripotent stem cells. Okita K, Ichisaka T, Yamanaka S, Nature 2007 448 313 317 10.1038/nature05934 17554338 (Pubitemid 47080336)
12. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, Bernstein BE, Jaenisch R, Nature 2007 448 318 324 10.1038/nature05944 17554336 (Pubitemid 47080337)
13. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE, Melton DA, Nat Biotechnol 2008 26 795 797 10.1038/nbt1418 18568017 (Pubitemid 351961456)
14. Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Kim JB, Zaehres H, Wu G, Gentile L, Ko K, Sebastiano V, Arauzo-Bravo MJ, Ruau D, Han DW, Zenke M, Scholer HR, Nature 2008 454 646 650 10.1038/nature07061 18594515
15. Induced human pluripotent stem cells: promises and open questions. Rolletschek A, Wobus AM, Biol Chem 2009 390 845 849 10.1515/BC.2009.103 19558327
16. A fresh look at iPS cells. Yamanaka S, Cell 2009 137 13 17 10.1016/j.cell.2009.03.034 19345179
17. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Marion RM, Strati K, Li H, Murga M, Blanco R, Ortega S, Fernandez-Capetillo O, Serrano M, Blasco MA, Nature 2009 460 1149 1153 10.1038/nature08287 19668189
18. A nonviral minicircle vector for. deriving human iPS cells. Jia F, Wilson KD, Sun N, Gupta DM, Huang M, Li Z, Panetta NJ, Chen ZY, Robbins RC, Kay MA, Longaker MT, Wu JC, Nat Methods 2010 7 197 199 10.1038/nmeth.1426 20139967
19. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G, Blak A, Cooper O, Mitalipova M, Isacson O, Jaenisch R, Cell 2009 136 964 977 10.1016/j.cell.2009.02.013 19269371
20. Generation of induced pluripotent stem cells using recombinant proteins. Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, Trauger S, Bien G, Yao S, Zhu Y, Siuzdak G, Schöler HR, Duan L, Ding S, Cell Stem Cell 2009 4 381 384 10.1016/j.stem.2009.04.005 19398399
21. Neural stem cells and Alzheimer's disease: challenges and hope. Zhongling F, Gang Z, Lei Y, Am J Alzheimers Dis Other Demen 2009 24 52 57 10.1177/1533317508327587 19116300
22. Adult neural stem cells in the mammalian central nervous system. Ma DK, Bonaguidi MA, Ming GL, Song H, Cell Res 2009 19 672 682 10.1038/cr.2009.56 19436263
23. Neural stem cells in aging and disease. Limke TL, Rao MS, J Cell Mol Med 2002 6 475 496 10.1111/j.1582-4934.2002.tb00451.x 12611637 (Pubitemid 44146432)
24. Mechanisms and functional implications of adult neurogenesis. Zhao C, Deng W, Gage FH, Cell 2008 132 645 660 10.1016/j.cell.2008.01.033 18295581 (Pubitemid 351253687)
25. Human neural stem cells improve cognitive function of aged brain. Qu T, Brannen CL, Kim HM, Sugaya K, Neuroreport 2001 12 1127 1132 10.1097/00001756- 200105080-00016 11338178 (Pubitemid 32374730)
26. 2010 Alzheimer's disease facts and figures. Alzheimer's Association, Alzheimers Dement 2010 6 158 194 10.1016/j.jalz.2010.01.009 20298981
27. Behavior of neural stem cells in the Alzheimer brain. Waldau B, Shetty AK, Cell Mol Life Sci 2008 65 2372 2384 10.1007/s00018-008-8053-y 18500448
28. Effects of engrafted neural stem cells in Alzheimer's disease rats. Xuan AG, Luo M, Ji WD, Long DH, Neurosci Lett 2009 450 167 171 10.1016/j.neulet.2008. 12.001 19070649
29. Neural stem cells improve. cognition via BDNF in a transgenic model of Alzheimer disease. Blurton-Jones M, Kitazawa M, Martinez-Coria H, Castello NA, Muller FJ, Loring JF, Yamasaki TR, Poon WW, Green KN, LaFerla FM, Proc Natl Acad Sci USA 2009 106 13594 13599 10.1073/pnas.0901402106 19633196
30. Adult stem cell therapies for neurological disorders: benefits beyond neuronal replacement? Boucherie C, Hermans E, J Neurosci Res 2009 87 1509 1521 10.1002/jnr.21970 19115417
31. Stem cell-based cell therapy in neurological diseases: a review. Kim SU, de Vellis J, J Neurosci Res 2009 87 2183 2200 10.1002/jnr.22054 19301431
32. Amyloid precursor protein trafficking, processing, and function. Thinakaran G, Koo EH, J Biol Chem 2008 283 29615 29619 10.1074/jbc.R800019200 18650430
33. 100 years and counting: prospects for defeating Alzheimer's disease. Roberson ED, Mucke L, Science 2006 314 781 784 10.1126/science.1132813 17082448 (Pubitemid 44706637)
34. Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease. Lee HG, Casadesus G, Zhu X, Castellani RJ, McShea A, Perry G, Petersen RB, Bajic V, Smith MA, Neurochem Int 2009 54 84 88 10.1016/j.neuint.2008.10.013 19114068
35. Regenerative medicine for neurological disorders. Park DH, Eve DJ, Chung YG, Sanberg PR, ScientificWorldJournal 2010 10 470 489 20305989
36. Enrichment of MCI and early Alzheimer's disease treatment trials using neurochemical and imaging candidate biomarkers. Hampel H, Broich K, J Nutr Health Aging 2009 13 373 375 10.1007/s12603-009-0048-3 19300885
37. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Kadir A, Andreasen N, Almkvist O, Wall A, Forsberg A, Engler H, Hagman G, Lärksäter M, Winblad B, Zetterberg H, Blennow K, Långström B, Nordberg A, Ann Neurol 2008 63 621 631 10.1002/ana.21345 18300284
38. Cholinesterase inhibitors: drugs looking for a disease? Maggini M, Vanacore N, Raschetti R, PLoS Med 2006 3 140 10.1371/journal.pmed.0030140 16597173
39. Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Connor B, Young D, Yan Q, Faull RL, Synek B, Dragunow M, Brain Res Mol Brain Res 1997 49 71 81 10.1016/S0169-328X(97)00125-3 9387865 (Pubitemid 27453116)
40. Practical issues in stem cell therapy for Alzheimer's disease. Sugaya K, Kwak YD, Ohmitsu O, Marutle A, Greig NH, Choumrina E, Curr Alzheimer Res 2007 4 370 377 10.2174/156720507781788936 17908039 (Pubitemid 47416630)
41. MCP-1-induced migration of NT2 neuroprogenitor cells involving APP signaling. Vrotsos EG, Sugaya K, Cell Mol Neurobiol 2009 29 373 381 10.1007/s10571-008-9329-3 19048368
42. Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine. Marutle A, Ohmitsu M, Nilbratt M, Greig NH, Nordberg A, Sugaya K, Proc Natl Acad Sci USA 2007 104 12506 12511 10.1073/pnas.0705346104 17640880 (Pubitemid 47206168)
43. Amyloid precursor protein regulates differentiation of human neural stem cells. Kwak YD, Brannen CL, Qu T, Kim HM, Dong X, Soba P, Majumdar A, Kaplan A, Beyreuther K, Sugaya K, Stem Cells Dev 2006 15 381 389 10.1089/scd.2006.15.381 16846375 (Pubitemid 44100015)
44. Neural stem cells constitutively secrete neurotrophic factors and promote extensive host axonal growth after spinal cord injury. Lu P, Jones LL, Snyder EY, Tuszynski MH, Exp Neurol 2003 181 115 129 10.1016/S0014-4886(03)00037-2 12781986 (Pubitemid 36629234)
45. Beneficial effects of hematopoietic growth factor therapy in chronic ischemic stroke in rats. Zhao LR, Berra HH, Duan WM, Singhal S, Mehta J, Apkarian AV, Kessler JA, Stroke 2007 38 2804 2811 10.1161/STROKEAHA.107.486217 17761920 (Pubitemid 47494021)
46. Brain repair by hematopoietic growth factors in a rat model of stroke. Zhao LR, Singhal S, Duan WM, Mehta J, Kessler JA, Stroke 2007 38 2584 2591 10.1161/STROKEAHA.106.476457 17656664 (Pubitemid 47329641)
47. Transplantation of vascular endothelial growth factor-transfected neural stem cells into the rat brain provides neuroprotection after transient focal cerebral ischemia. Zhu W, Mao Y, Zhao Y, Zhou LF, Wang Y, Zhu JH, Zhu Y, Yang GY, Neurosurgery 2005 57 325 333 discussion 325-333 10.1227/01.NEU.0000166682. 50272.BC 16094163 (Pubitemid 41098708)
48. Autologous mesenchymal stem cell transplantation in stroke patients. Bang OY, Lee JS, Lee PH, Lee G, Ann Neurol 2005 57 874 882 10.1002/ana.20501 15929052 (Pubitemid 40798626)
49. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH, Bang OY, Stem Cells 2010 28 1099 1106 10.1002/stem.430 20506226
50. Mechanisms underlying inflammation in neurodegeneration. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH, Cell 2010 140 918 934 10.1016/j.cell.2010. 02.016 20303880
51. A Drosophila model of Parkinson's disease. Feany MB, Bender WW, Nature 2000 404 394 398 10.1038/35006074 10746727 (Pubitemid 30164341)
52. Molecular pathways of neurodegeneration in Parkinson's disease. Dawson TM, Dawson VL, Science 2003 302 819 822 10.1126/science.1087753 14593166 (Pubitemid 37339614)
53. Will stem cell biology generate new therapies for Parkinson's disease? McKay R, Kittappa R, Neuron 2008 58 659 661 10.1016/j.neuron.2008.05.016 18549778 (Pubitemid 351778471)
54. Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson's disease. Park HJ, Lee PH, Bang OY, Lee G, Ahn YH, J Neurochem 2008 107 141 151 10.1111/j.1471-4159.2008.05589.x 18665911
55. Olfactory mucosa is a potential source for autologous stem cell therapy for Parkinson's disease. Murrell W, Wetzig A, Donnellan M, Feron F, Burne T, Meedeniya A, Kesby J, Bianco J, Perry C, Silburn P, Mackay-Sim A, Stem Cells 2008 26 2183 2192 10.1634/stemcells.2008-0074 18535154
56. Transplantation of human neural stem cells exerts neuroprotection in a rat model of Parkinson's disease. Yasuhara T, Matsukawa N, Hara K, Yu G, Xu L, Maki M, Kim SU, Borlongan CV, J Neurosci 2006 26 12497 12511 10.1523/JNEUROSCI.3719-06.2006 17135412 (Pubitemid 44864515)
57. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Kim JH, Auerbach JM, Rodriguez-Gomez JA, Velasco I, Gavin D, Lumelsky N, Lee SH, Nguyen J, Sanchez-Pernaute R, Bankiewicz K, McKay R, Nature 2002 418 50 56 10.1038/nature00900 12077607 (Pubitemid 34742566)
58. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Wernig M, Zhao JP, Pruszak J, Hedlund E, Fu D, Soldner F, Broccoli V, Constantine-Paton M, Isacson O, Jaenisch R, Proc Natl Acad Sci USA 2008 105 5856 5861 10.1073/pnas.0801677105 18391196 (Pubitemid 351758462)
59. Dopaminergic neurons derived from human induced pluripotent stem cells survive and integrate into 6-OHDA-lesioned rats. Cai J, Yang M, Poremsky E, Kidd S, Schneider JS, Iacovitti L, Stem Cells Dev 2010 19 1017 1023 10.1089/scd.2009.0319 19824823
60. Novel etiological and therapeutic strategies for neurodiseases: RNA editing enzyme abnormality in sporadic amyotrophic lateral sclerosis. Hideyama T, Yamashita T, Nishimoto Y, Suzuki T, Kwak S, J Pharmacol Sci 2010 113 9 13 10.1254/jphs.09R21FM 20424386
61. Motor neuron degeneration promotes neural progenitor cell proliferation, migration, and neurogenesis in the spinal cords of amyotrophic lateral sclerosis mice. Chi L, Ke Y, Luo C, Li B, Gozal D, Kalyanaraman B, Liu R, Stem Cells 2006 24 34 43 10.1634/stemcells.2005-0076 16099995
62. Neural stem cells LewisX+ CXCR4+ modify disease progression in an amyotrophic lateral sclerosis model. Corti S, Locatelli F, Papadimitriou D, Del Bo R, Nizzardo M, Nardini M, Donadoni C, Salani S, Fortunato F, Strazzer S, Bresolin N, Comi GP, Brain 2007 130 1289 1305 10.1093/brain/awm043 17439986 (Pubitemid 47355948)
63. Adult glial precursor proliferation in mutant SOD1G93A mice. Magnus T, Carmen J, Deleon J, Xue H, Pardo AC, Lepore AC, Mattson MP, Rao MS, Maragakis NJ, Glia 2008 56 200 208 10.1002/glia.20604 18023016 (Pubitemid 350292312)
64. Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Lepore AC, Rauck B, Dejea C, Pardo AC, Rao MS, Rothstein JD, Maragakis NJ, Nat Neurosci 2008 11 1294 1301 10.1038/nn.2210 18931666
65. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, Croft GF, Saphier G, Leibel R, Goland R, Wichterle H, Henderson CE, Eggan K, Science 2008 321 1218 1221 10.1126/science.1158799 18669821
66. Stem cell treatment in amyotrophic lateral sclerosis. Mazzini L, Mareschi K, Ferrero I, Vassallo E, Oliveri G, Nasuelli N, Oggioni GD, Testa L, Fagioli F, J Neurol Sci 2008 265 78 83 10.1016/j.jns.2007.05.016 17582439
67. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a phase I clinical trial. Mazzini L, Ferrero I, Luparello V, Rustichelli D, Gunetti M, Mareschi K, Testa L, Stecco A, Tarletti R, Miglioretti M, Fava E, Nasuelli N, Cisari C, Massara M, Vercelli R, Oggioni GD, Carriero A, Cantello R, Monaco F, Fagioli F, Exp Neurol 2010 223 229 237 10.1016/j.expneurol.2009.08. 007 19682989
68. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Weiner HL, Ann Neurol 2009 65 239 248 10.1002/ana.21640 19334069
69. Promising treatments of tomorrow for multiple sclerosis. Harrison DM, Calabresi PA, Ann Indian Acad Neurol 2009 12 283 290 10.4103/0972-2327.58279 20182576
70. Neuroprotective effect of transplanted human embryonic stem cell-derived neural precursors in an animal model of multiple sclerosis. Aharonowiz M, Einstein O, Fainstein N, Lassmann H, Reubinoff B, Ben-Hur T, PLoS One 2008 3 3145 10.1371/journal.pone.0003145 18773082
71. Regeneration and repair in multiple sclerosis: the role of cell transplantation. Pluchino S, Zanotti L, Brini E, Ferrari S, Martino G, Neurosci Lett 2009 456 101 106 10.1016/j.neulet.2008.03.097 19429143
72. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G, Oyama Y, Russell EJ, Stern J, Muraro P, Rose J, Testori A, Bucha J, Jovanovic B, Milanetti F, Storek J, Voltarelli JC, Burns WH, Lancet Neurol 2009 8 244 253 10.1016/S1474-4422(09) 70017-1 19186105
73. Human stem cell ethics: beyond the embryo. Sugarman J, Cell Stem Cell 2008 2 529 533 10.1016/j.stem.2008.05.005 18522846 (Pubitemid 351729218)
74. New ISSCR guidelines underscore major principles for responsible translational stem cell research. Hyun I, Lindvall O, Ahrlund-Richter L, Cattaneo E, Cavazzana-Calvo M, Cossu G, De Luca M, Fox IJ, Gerstle C, Goldstein RA, Hermerén G, High KA, Kim HO, Lee HP, Levy-Lahad E, Li L, Lo B, Marshak DR, McNab A, Munsie M, Nakauchi H, Rao M, Rooke HM, Valles CS, Srivastava A, Sugarman J, Taylor PL, Veiga A, Wong AL, Zoloth L, Daley GQ, Cell Stem Cell 2008 3 607 609 10.1016/j.stem.2008.11.009 19041777